View all ILC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recap
Three PER Pulse™ Recaps presenting key topics from the 16th Annual International Lung Cancer Congress®, which was held on July 30 - August 1, 2015.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen Inc; Astellas; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Biodesix Inc; Bristol-Myers Squibb; Celgene Corporation; Clovis Oncology; Genentech; Lilly; and Novartis Pharmaceuticals Corporation.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Community Practice Connections™: 16th Annual International Lung Cancer Congress®


Release Date: October 6, 2015
Expiration Date: October 6, 2016
Media: Internet - based

Activity Overview

Community Practice Connections™: 16th Annual International Lung Cancer Congress® consists of a series of interactive clinical vignettes, short video interviews of leading lung cancer experts, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

CME Activity Table of Contents

  • A Patient With Epidermal Growth Factor Receptor (EGFR) Mutation-Positive NSCLC
  • A Patient With ALK-Rearranged NSCLC
  • A Patient with Advanced Lung Adenocarcinoma and Wild-Type EGFR, ALK, and KRAS Genes
  • A Patient With Advanced NSCLC and Squamous Histology

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This online activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.


Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Summarize appropriate biomarker testing/re-testing strategies to be applied based upon patient and disease characteristics
  • Describe strategies to optimize treatment plans in patients with lung cancer, considering factors such as efficacy of a drug in different settings, prior therapies, existing comorbidities, and disease characteristics
  • Evaluate data on new agents and approaches in development for lung cancer
  • Review recent data on immune-checkpoint inhibition with anti-PD-1, anti-PD-L1, and anti-CTLA-4 blockade
  • Assess how emerging data on the use of molecularly targeted agents can be used to improve the treatment of patients with NSCLC
  • Identify appropriate clinical trials examining novel agents that are designed to benefit patients with lung cancer


Faculty, Staff, and Planners' Disclosures

Faculty

David R. Gandara, MD
Professor of Medicine, Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
University of California, Davis Comprehensive Cancer Center
Sacramento, CA
Disclosures: Grant/research support: Abbott, Bristol Myers Squib, Genentech, ImClone, Lilly, Merck, Novartis, and Pfizer; Consultant: Amgen, AstraZeneca, Boehringer-Ingelheim, BioMarin, Bristol Myers Squib, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, Response Genetics Inc, and Synta.
 

Roy S. Herbst, MD, PhD
Professor of Medicine, Division of Hematology/Oncology
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosures: Grant/research support: Genentech; Consultant: Ariad, Eli Lilly, Genentech/Roche, Gilead, Merck, and Pfizer.
 

Corey J. Langer, MD, FACP
Professor of Medicine, Hematology/Oncology Division
University of Pennsylvania
Director, Thoracic Oncology
Abramson Comprehensive Cancer Center
Philadelphia, PA
Disclosures: Grant/research support: Advantagene, AZ, BI, BMS, Clovis, Genentech/Roche, GSK, Inovio, Merck, Nektar; Consultant: Abbott, AZ/Medimmune, BI, Clovis, Genentech/Roche, Lilly, Pfizer. Other: DSMC: Amgen, Lilly, Peregrine, Synta.
 

Naiyer Rizvi, MD
Professor of Medicine, Division of Hematology/Oncology
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY
Disclosures: Consultant: AstraZeneca, BMS, Merck, Roche
 

The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC (Ann C. Lichti, CHCP; and Tiffany Fattizzi); David Lee, PhD (medical writer;, and Margie Schulz (medical reviewer).


Accreditation/Designation of Credit Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen Inc; Astellas; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Biodesix Inc; Bristol-Myers Squibb; Celgene Corporation; Clovis Oncology; Genentech; Lilly; and Novartis Pharmaceuticals Corporation.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.


Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By